Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study.

Annals of hematology - 4 Mar 2026

Barbui Tiziano, Thiele Jürgen, Alvarez-Larran Alberto, Rambaldi Alessandro, Vannucchi Alessandro Maria, Tefferi Ayalew

Abstract excerpt

Essential thrombocythemia (ET) and polycythemia vera (PV) are traditionally viewed as distinct Philadelphia chromosome–negative myeloproliferative neoplasms, yet both frequently harbor the JAK2V617F mutation, suggesting a biological continuum. Occasional reports describe progression from JAK2-mutated ET to overt PV, but this evolution has never been systematically studied. We present the background and design of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Case-Control Studies
Share to Disease Progression

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Multicenter Studies as Topic

Share to Observational Studies as Topic

Share to Polycythemia Vera

Share to Research Design

Share to Thrombocythemia, Essential

Source

Open in PubMed Open full text

Identifiers

PMID: 41776088
DOI: 10.1007/s00277-026-06898-1
PMCID: PMC12957057

Genes

JAK2
ELN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From essential thrombocythemia to polycythemia vera (ET-2-PV): rationale and design of a multicenter ELN study.PMID 41776088Read ↗

Polycythemia vera.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.Semantic proximity Read ↗

Advances in Molecular Understanding of Polycythemia Vera, Essential Thrombocythemia, and Primary Myelofibrosis: Towards Precision MedicineSemantic proximity Read ↗

Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches.Semantic proximity Read ↗

Leukemic evolution of polycythemia vera and essential thrombocythemia: genomic profiles predict time to transformation.Semantic proximity Read ↗

Molecular Characterization of Polycythemia VeraSemantic proximity Read ↗

One thousand patients with essential thrombocythemia: the Mayo Clinic experience.Semantic proximity Read ↗

Profile of Philadelphia Chromosome Negative (Ph-) Myeloproliferative Neoplasm with Special Emphasis on Vascular Thrombotic Events and the Response to Cytoreductive Therapy in Polycythemia Vera and Essential Thrombocythemia Patients: A Single Center Study from Kerala.Semantic proximity Read ↗

The 2014 BCSH criteria and the 2016 WHO criteria for essential thrombocythemia: A comparison in a large-scale cohort.Semantic proximity Read ↗

JAK2 ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia veraSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.